Pidilizumab

• Description :

  Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].

• Product Name Alternative :

  CT-011; MDV9300

• UNSPSC :

  12352203

• Target :

  PD-1/PD-L1

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pidilizumab.html

• Purity :

  99.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Pidilizumab]

• Molecular Weight :

  (144.626 kDa)

• References & Citations :

  [1]Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15 (1) :69-77.|[2]Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40 (14) :6450-6462.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [1036730-42-3]